Zacks Research Comments on Integer’s Q2 Earnings (NYSE:ITGR)

Integer Holdings Co. (NYSE:ITGR) – Investment analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for Integer in a research report issued on Thursday, March 13th. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings per share of $1.44 for the quarter, up from their prior estimate of $1.43. The consensus estimate for Integer’s current full-year earnings is $6.01 per share. Zacks Research also issued estimates for Integer’s Q3 2025 earnings at $1.57 EPS, FY2025 earnings at $5.98 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.54 EPS, FY2026 earnings at $6.58 EPS and FY2027 earnings at $7.15 EPS.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The business had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%.

Several other research analysts have also recently weighed in on ITGR. Oppenheimer cut Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Benchmark raised their target price on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 target price on shares of Integer in a research note on Tuesday, December 3rd. Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Finally, Truist Financial raised their target price on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Integer currently has a consensus rating of “Moderate Buy” and an average price target of $149.00.

Integer Trading Up 1.2 %

Shares of ITGR stock opened at $119.25 on Monday. The stock has a 50-day simple moving average of $133.82 and a 200 day simple moving average of $132.69. Integer has a fifty-two week low of $107.11 and a fifty-two week high of $146.36. The stock has a market capitalization of $4.01 billion, a P/E ratio of 35.49, a P/E/G ratio of 1.72 and a beta of 1.24. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently modified their holdings of ITGR. Wealth Enhancement Advisory Services LLC acquired a new stake in Integer during the 4th quarter worth about $208,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Integer during the 4th quarter worth about $7,889,000. Brucke Financial Inc. acquired a new stake in Integer during the 4th quarter worth about $564,000. Azzad Asset Management Inc. ADV boosted its position in Integer by 4.9% during the 4th quarter. Azzad Asset Management Inc. ADV now owns 12,138 shares of the medical equipment provider’s stock worth $1,609,000 after acquiring an additional 566 shares during the period. Finally, Vise Technologies Inc. boosted its position in Integer by 8.3% during the 4th quarter. Vise Technologies Inc. now owns 4,702 shares of the medical equipment provider’s stock worth $623,000 after acquiring an additional 362 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.